Preclinical Testing News and Research

RSS

Scientists develop and test a new model of traumatic brain injury in zebrafish

A group of scientists, which included researchers from the Ural Federal University (UrFU), have developed and successfully tested a new model of traumatic brain injury (TBI) in zebrafish.

15 Sep 2022

CRISPR genome-editing technology can be used as a tool to discover RNA therapeutics for lung cancer

An international team of scientists have demonstrated for the first time that CRISPR genome-editing technology can be used as a tool to find new gene therapies for lung cancer.

24 Aug 2022

IU researchers evaluate the efficacy of a failed clinical trial drug for Alzheimer's using rigorous pipeline

Most drugs developed to treat Alzheimer's disease have for years been ineffective in clinical trials. Researchers from Indiana University School of Medicine recently evaluated the efficacy of a failed clinical trial drug using their rigorous pipeline.

25 Jul 2022

New mouse model faithfully mimics brain damage caused by severe Rift Valley Fever virus infection

A new mouse model identified by virologists from the University of Pittsburgh might revolutionize development of therapies targeting brain inflammation caused by Rift Valley Fever virus (RVFV).

15 Jul 2022

Innovative strategy for treating non-small cell lung cancer when radiotherapy fails

Lung cancer is the most common cancer in the world, with 2.2 million new cases and around 1.8 million deaths in 2020 alone.

4 Jul 2022

Researchers create first bona fide mouse model of Merkel cell carcinoma

A team of researchers at the University of Michigan Rogel Cancer Center were the first to generate a bona fide mouse model of a Merkel cell carcinoma, a rare and potentially aggressive form of skin cancer.

15 Jun 2022

Scientists create a bioengineered 3D model that mimics the biology of two rare neuromuscular diseases

A scientific team supported by the National Institutes of Health has created a tiny, bioengineered 3-D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, a pair of rare, devastating neuromuscular diseases.

19 Apr 2022

INRS professor developing a glycoconjugate vaccine for melioidosis

The threat from Melioidosis is real. The bacterium that causes this infectious multisymptom illness is resistant to antibiotics, making diagnosis and treatment more complex and resulting in a mortality rate of up to 50%.

24 Mar 2022

CD63-expressing extracellular vesicles neutralize SARS-CoV-2 variants of concern

Researchers evaluate antiviral effects of CD63 tetraspanin extracellular vesicles against SARS-CoV-2 and HIV-1.

22 Mar 2022

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

In a new study, a team of researchers developed a vaccine candidate with the SARS-CoV-2 spike (S) glycoprotein coated onto lipid vesicles which resembles virus-like particles.

26 Jan 2022

Genome editing in vascular endothelial cells made possible with a powerful new delivery system

Northwestern Medicine scientists developed a unique nanoparticle to deliver genome editing technology, including CRISPR/Cas9, to endothelial cells, which line blood vessel walls.

16 Jan 2022

Unique nanoparticle can deliver genome editing technology to endothelial cells

The lab of Youyang Zhao, PhD, from Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago developed a unique nanoparticle to deliver genome editing technology, including CRISPR/Cas9, to endothelial cells, which are cells that line blood vessel walls.

4 Jan 2022

Study finds atazanavir inhibits main SARS-CoV-2 protease

Research shows that ATV has different antiviral activity compared to PAXLOVID™, encouraging further research.

29 Nov 2021

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.

23 Nov 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021

New analysis reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Oncotarget published "Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells" which reported that to ascertain phenotypical differences between these two distinct culture conditions, these authors carried out a comparative proteomic analysis of a membrane fraction obtained from 3D- and 2D-cultured NSCLC model cell line NCI-H23.

29 Sep 2021

Cardiothoracic surgeons implant novel type of artificial heart in a female patient

A cardiothoracic surgical team with UofL Health – Jewish Hospital and the University of Louisville has performed the world's first Aeson® bioprosthetic total artificial heart implantation in a female patient. The investigational device, currently intended as a bridge to heart transplant, is part of an Early Feasibility Study (EFS) sponsored by CARMAT, a French medical device company, in partnership with UofL, UofL Health – Jewish Hospital and the UofL Health – Trager Transplant Center.

22 Sep 2021

Study could pave way for an effective approach to amblyopia treatment

Amblyopia is the most common cause of vision loss in children, according to the U.S. National Eye Institute.

1 Sep 2021

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

New compounds can provide a breakthrough in the treatment of neurodegenerative pathologies

Russian scientists have synthesized chemical compounds that can stop the degeneration of neurons in Alzheimer's, Parkinson's, and other severe brain pathologies. These substances can provide a breakthrough in the treatment of neurodegenerative pathologies.

19 Jul 2021